Rallybio Corporation Investor Relations Material
Latest events
Status Update
Rallybio Corporation
Q1 2025
8 May, 2025
Q4 2024
13 Mar, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Rallybio Corporation
Access all reports
Rallybio Corporation is a biotechnology company focused on developing therapies for rare and severe diseases. The company specializes in antibody and protein-based treatments targeting immune and hematological disorders. Its research and development efforts aim to address conditions with high unmet medical needs through clinical trials and collaborations with scientific partners. The company is headquartered in New Haven, Connecticut, and its shares are listed on the NASDAQ.
Key slides for Rallybio Corporation
Status Update
Rallybio Corporation
Status Update
Rallybio Corporation
Latest articles
)
D. E. Shaw & Co: Inside the Quiet Giant of Quant Finance
A deep dive into D. E. Shaw's evolution from a $28M quant startup to a $65B hedge fund giant, built on research, computing, and quiet consistency.
2 Jul 2025
)
Pershing Square Capital Management: Conviction, Reinvention, and Contrarian Investing
Pershing Square Capital Management has grown into a top-tier hedge fund through reinvention, conviction, and focus on long-term value creation.
2 Jul 2025
)
Eli Lilly: The Pharma Giant Behind Mounjaro and Zepbound
Eli Lilly's journey from insulin pioneer to global pharma giant, leading innovation in diabetes, obesity, and the future of metabolic health.
30 Jun 2025
Ticker symbol
RLYB
Country
🇺🇸 United States